董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dwight Egan | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 72 | 52.88万美元 | 3.12 | 2026-09-03 |
| Richard Serbin | 男 | Director | 81 | 13.78万美元 | 1.14 | 2026-09-03 |
| Eugene Durenard | 男 | Director | 56 | 14.08万美元 | 1.07 | 2026-09-03 |
| Edward Murphy | 男 | Director | 61 | 13.78万美元 | 1.28 | 2026-09-03 |
| James Nelson | 男 | Director | 73 | 13.78万美元 | 1.23 | 2026-09-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dwight Egan | 男 | Chairman of the Board and Chief Executive Officer and Director and President | 72 | 52.88万美元 | 3.12 | 2026-09-03 |
| Brian Brown | 男 | Chief Financial Officer and Secretary | 50 | 42.13万美元 | 2.24 | 2026-09-03 |
| Richard Abbott | 男 | President | 54 | 36.00万美元 | 2.31 | 2026-09-03 |
董事简历
中英对照 | 中文 | 英文- Dwight Egan
-
DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation（无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商，面向27000名个人和专业投资者）的高级执行官（1995年至1999年）。他从1984年到1995年共同创立并担任Broadcasting International，Inc.的首席执行官和董事会主席，当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
Dwight Egan serves as Co Diagnostics, Inc.'s Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real time financial market data, news and sophisticated fixed income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering. - DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation（无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商，面向27000名个人和专业投资者）的高级执行官（1995年至1999年）。他从1984年到1995年共同创立并担任Broadcasting International，Inc.的首席执行官和董事会主席，当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
- Dwight Egan serves as Co Diagnostics, Inc.'s Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real time financial market data, news and sophisticated fixed income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
- Richard Serbin
-
RichardS.Serbin于2017年5月加入我们的董事会，目前担任梦百合行业许多公司的顾问。他曾担任Life Science Institute，LLC的公司发展总裁兼内部法律顾问（2013年6月1日至2014年7月15日）。Serbin先生是一名全球战略顾问、药剂师和企业家，拥有药剂学和法律方面的证书，并在梦百合行业担任了40多年的FDA监管律师和专利律师。他于2017年1月被任命为Cure Pharmaceutical的咨询委员会成员，并自2015年9月起担任Prime Access，Inc.的咨询委员会成员。Serbin先生自2014年11月18日起担任Rapid Nutrition plc的董事。他从2013年5月到2014年6月担任ViroPro Inc.董事。他从2006年10月到2007年9月担任Mazal Plant Pharmaceuticals Inc.业务顾问委员会主管，也曾担任其业务顾问委员会成员。他从2002年7月到2005年9月15日担任Optigenex Inc.的首席执行官，从2004年7月到2005年9月担任董事。Serbin从1999年1月到2002年7月担任多家制药公司顾问。他曾担任Bradley Pharmaceuticals的总裁。他曾担任Ortho Pharmaceuticals公司（强生公司的子公司）的企业发展Vice President，并在露华浓强生公司公司和先灵葆雅公司实践专利和FDA法律。他曾担任Schering Plough Corporation的专利律师，以及Revlon Corporation、Johnson and Johnson Corporation的首席FDA法律顾问。随后，他在露华浓公司（Revlon Corporation）工作，担任其首席食品、药品和化妆品顾问。他创立了Radius Scientific Corporation。他曾担任强生公司（J&；J&；8217；）的企业发展Vice President，后来领导了一家基于斯坦福医学院（Stanford Medical School）开发的技术的成功上市公司。Serbin先生职业生涯的很大一部分时间专注于国际市场和客户。在J&J时，Serbin先生担任16家美国和国际子公司的董事会成员，包括Ethicon，Ortho，J&J Consumer Products，Pittman-Moore，MC Neil和J&J Development Corporation。他曾从事多个国际收购和战略关系，并任职其几个国际子公司的董事会，包括印度、香港、日本、台湾、德国和英国的子公司。Serbin先生拥有罗格斯大学（Rutgers University）和罗格斯大学药学院（Rutgers University College of Pharmacy）的B.S.和B.Pharmacy，Seton Hall法学院的法学博士学位和纽约大学法学院（NYU Law School）的贸易法规和法律硕士学位。
Richard Serbin has been a member of Co Diagnostics, Inc.'s board of directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. Since January 2024, he has served as Chairman of the Board of Directors of Platform Pharmaceuticals. He was the President of Corporate Development and In House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, and practiced Patent and FDA law at Revlon Johnson & Johnson and Schering Plough.He worked on multiple international acquisitions and strategic relationships, and sat on the board of directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master's Degree in Trade Regulations and Law from NYU Law School. - RichardS.Serbin于2017年5月加入我们的董事会，目前担任梦百合行业许多公司的顾问。他曾担任Life Science Institute，LLC的公司发展总裁兼内部法律顾问（2013年6月1日至2014年7月15日）。Serbin先生是一名全球战略顾问、药剂师和企业家，拥有药剂学和法律方面的证书，并在梦百合行业担任了40多年的FDA监管律师和专利律师。他于2017年1月被任命为Cure Pharmaceutical的咨询委员会成员，并自2015年9月起担任Prime Access，Inc.的咨询委员会成员。Serbin先生自2014年11月18日起担任Rapid Nutrition plc的董事。他从2013年5月到2014年6月担任ViroPro Inc.董事。他从2006年10月到2007年9月担任Mazal Plant Pharmaceuticals Inc.业务顾问委员会主管，也曾担任其业务顾问委员会成员。他从2002年7月到2005年9月15日担任Optigenex Inc.的首席执行官，从2004年7月到2005年9月担任董事。Serbin从1999年1月到2002年7月担任多家制药公司顾问。他曾担任Bradley Pharmaceuticals的总裁。他曾担任Ortho Pharmaceuticals公司（强生公司的子公司）的企业发展Vice President，并在露华浓强生公司公司和先灵葆雅公司实践专利和FDA法律。他曾担任Schering Plough Corporation的专利律师，以及Revlon Corporation、Johnson and Johnson Corporation的首席FDA法律顾问。随后，他在露华浓公司（Revlon Corporation）工作，担任其首席食品、药品和化妆品顾问。他创立了Radius Scientific Corporation。他曾担任强生公司（J&；J&；8217；）的企业发展Vice President，后来领导了一家基于斯坦福医学院（Stanford Medical School）开发的技术的成功上市公司。Serbin先生职业生涯的很大一部分时间专注于国际市场和客户。在J&J时，Serbin先生担任16家美国和国际子公司的董事会成员，包括Ethicon，Ortho，J&J Consumer Products，Pittman-Moore，MC Neil和J&J Development Corporation。他曾从事多个国际收购和战略关系，并任职其几个国际子公司的董事会，包括印度、香港、日本、台湾、德国和英国的子公司。Serbin先生拥有罗格斯大学（Rutgers University）和罗格斯大学药学院（Rutgers University College of Pharmacy）的B.S.和B.Pharmacy，Seton Hall法学院的法学博士学位和纽约大学法学院（NYU Law School）的贸易法规和法律硕士学位。
- Richard Serbin has been a member of Co Diagnostics, Inc.'s board of directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. Since January 2024, he has served as Chairman of the Board of Directors of Platform Pharmaceuticals. He was the President of Corporate Development and In House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, and practiced Patent and FDA law at Revlon Johnson & Johnson and Schering Plough.He worked on multiple international acquisitions and strategic relationships, and sat on the board of directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master's Degree in Trade Regulations and Law from NYU Law School.
- Eugene Durenard
-
Eugene Durenard于2019年6月加入我们的董事会，他是Dyperbolic Holdings的创始人兼首席执行官，该公司是一家总部位于瑞士的控股，管理咨询和战略咨询公司，专门从事梦百合。Eugene拥有跨越20年的投资和创业经验。在过去的7年里，他一直与家族办公室合作，从事直接投资和专注于生命科学的慈善事业。他是生物技术和医疗技术领域几家私营公司的顾问委员会成员，也是专注于梦百合的Impact Venture Fund的成员。在伦敦所罗门兄弟（Salomon Brothers）和瑞士信贷（Credit Suisse）从事自营研究和交易的最初职业生涯后，他在百慕大联合创立了猎户座投资管理公司（Orion Investment Management），专门从事机构和私人客户的量化资产负债管理。他随后将其出售给Capital G Bank，并共同领导他们的资产管理。尤金花了几年时间与全球40多个生命科学创新集群的代表、经营梦百合企业的家庭和行业领袖建立了个人联系。他定期访问实验室和孵化器，会见领先的科学家和创新者，以跟上当前的趋势和发展。他的建议是基于结合科学的深入知识、竞争力和金融专业知识的透彻分析。他在资产负债管理行业杂志上发表了多篇文章，并在2013年出版了《专业自动化交易理论与实践》一书。他获有Harvard University数学博士学位。
Eugene Durenard has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss based holding, management consulting and strategy advisory company specialized in healthcare. For several years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on advisory and executive boards of a few private companies in the Biotech and MedTech sectors, some of which he co founded. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co headed their asset management. Dr. Durenard spent several years establishing personal connections with various international clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset liability management, in public health as well as the book "Professional Automated Trading — Theory and Practice" (Wiley 2013). He has a PhD in Mathematics from Harvard University. - Eugene Durenard于2019年6月加入我们的董事会，他是Dyperbolic Holdings的创始人兼首席执行官，该公司是一家总部位于瑞士的控股，管理咨询和战略咨询公司，专门从事梦百合。Eugene拥有跨越20年的投资和创业经验。在过去的7年里，他一直与家族办公室合作，从事直接投资和专注于生命科学的慈善事业。他是生物技术和医疗技术领域几家私营公司的顾问委员会成员，也是专注于梦百合的Impact Venture Fund的成员。在伦敦所罗门兄弟（Salomon Brothers）和瑞士信贷（Credit Suisse）从事自营研究和交易的最初职业生涯后，他在百慕大联合创立了猎户座投资管理公司（Orion Investment Management），专门从事机构和私人客户的量化资产负债管理。他随后将其出售给Capital G Bank，并共同领导他们的资产管理。尤金花了几年时间与全球40多个生命科学创新集群的代表、经营梦百合企业的家庭和行业领袖建立了个人联系。他定期访问实验室和孵化器，会见领先的科学家和创新者，以跟上当前的趋势和发展。他的建议是基于结合科学的深入知识、竞争力和金融专业知识的透彻分析。他在资产负债管理行业杂志上发表了多篇文章，并在2013年出版了《专业自动化交易理论与实践》一书。他获有Harvard University数学博士学位。
- Eugene Durenard has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss based holding, management consulting and strategy advisory company specialized in healthcare. For several years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on advisory and executive boards of a few private companies in the Biotech and MedTech sectors, some of which he co founded. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co headed their asset management. Dr. Durenard spent several years establishing personal connections with various international clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset liability management, in public health as well as the book "Professional Automated Trading — Theory and Practice" (Wiley 2013). He has a PhD in Mathematics from Harvard University.
- Edward Murphy
-
EdwardL.Murphy于2019年6月加入我们的董事会，目前担任私人投资公司Dover Investments Ltd.的高级副总裁和合伙人。在他的整个职业生涯中，Murphy&8217；先生的职责包括房地产和金融服务的各种类型的投资项目的投资分析。目前，Murphy先生任职于几家加拿大公开报告公司的董事会，这些公司在各个行业都有利益。他自2016年1月以来一直担任Empire Minerals Corporation Inc.的董事，自2011年6月以来一直担任DigiCrypts Blockchain Solutions Inc.的董事，自2018年2月以来一直担任Lakefield Marketing Corporation的董事，自1997年4月30日以来一直担任Mosport Park Entertainment Corporation的董事。他于2003年5月至2017年12月担任Aurquest Resources的董事。
Edward Murphy has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Since December 1999, Mr. Murphy has served as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy's duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian and American publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at the Mosport Park Entertainment Corporation from April 30, 1997 until it became Digicrypts Blockchain Solutions Inc. in June 2011 until he resigned in November 2022, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, and at Essex Oil Ltd. since July 2021, and at Darkhorse Technologies Ltd. since November 2021. He served as a Director at Aurquest Resources from May 2003 to December 2017. He has also served as Director at E Ventures Inc. since April 2023. - EdwardL.Murphy于2019年6月加入我们的董事会，目前担任私人投资公司Dover Investments Ltd.的高级副总裁和合伙人。在他的整个职业生涯中，Murphy&8217；先生的职责包括房地产和金融服务的各种类型的投资项目的投资分析。目前，Murphy先生任职于几家加拿大公开报告公司的董事会，这些公司在各个行业都有利益。他自2016年1月以来一直担任Empire Minerals Corporation Inc.的董事，自2011年6月以来一直担任DigiCrypts Blockchain Solutions Inc.的董事，自2018年2月以来一直担任Lakefield Marketing Corporation的董事，自1997年4月30日以来一直担任Mosport Park Entertainment Corporation的董事。他于2003年5月至2017年12月担任Aurquest Resources的董事。
- Edward Murphy has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Since December 1999, Mr. Murphy has served as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy's duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian and American publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at the Mosport Park Entertainment Corporation from April 30, 1997 until it became Digicrypts Blockchain Solutions Inc. in June 2011 until he resigned in November 2022, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, and at Essex Oil Ltd. since July 2021, and at Darkhorse Technologies Ltd. since November 2021. He served as a Director at Aurquest Resources from May 2003 to December 2017. He has also served as Director at E Ventures Inc. since April 2023.
- James Nelson
-
James Nelson是Sunworks，Inc.的退休董事长兼首席执行官，这是一家纳斯达克上市的商业、农业和住宅太阳能集成商，他在2010年10月帮助创立了该公司。Nelson先生目前担任另外三家上市公司的战略顾问。Jim职业生涯的大部分时间都在Private Equity任职，担任Peterson Partners和Millennial Capital Partners的普通合伙人。除了他的投资和财务责任，他曾担任他的两个公司（投资组合公司）的首席执行官。在从事私募股权投资之前，纳尔逊先生曾担任Banana Republic的市场营销Vice President，在那里他管理公司范围内的市场营销，以及公司的国际扩张计划。他也曾担任Banana Republic公司的目录部门总经理。他曾担任SAGA Corporation（一家数十亿美元的食品服务公司）的营销和企业发展Vice President。Jim于35年前在Bain and Company（一家商业战略咨询公司）开始他的执行职业生涯，在那里他管理四大洲的顾问团队。Nelson先生在杨百翰大学（Brigham Young University）获得工商管理硕士学位，在那里他以优等成绩毕业，并被评为杰出的工商管理硕士毕业生。
James Nelson has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms' portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company wide marketing, as well as the company's international expansion initiative. He was also general manager for Banana Republic's catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi billion dollar food service company. Mr. Nelson began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate. Mr. Nelson's advice to the board of directors from his experiences as a chief executive officer, strategic advisor and knowledge of capital markets greatly benefits Co Diagnostics, Inc.'s Board of Directors. - James Nelson是Sunworks，Inc.的退休董事长兼首席执行官，这是一家纳斯达克上市的商业、农业和住宅太阳能集成商，他在2010年10月帮助创立了该公司。Nelson先生目前担任另外三家上市公司的战略顾问。Jim职业生涯的大部分时间都在Private Equity任职，担任Peterson Partners和Millennial Capital Partners的普通合伙人。除了他的投资和财务责任，他曾担任他的两个公司（投资组合公司）的首席执行官。在从事私募股权投资之前，纳尔逊先生曾担任Banana Republic的市场营销Vice President，在那里他管理公司范围内的市场营销，以及公司的国际扩张计划。他也曾担任Banana Republic公司的目录部门总经理。他曾担任SAGA Corporation（一家数十亿美元的食品服务公司）的营销和企业发展Vice President。Jim于35年前在Bain and Company（一家商业战略咨询公司）开始他的执行职业生涯，在那里他管理四大洲的顾问团队。Nelson先生在杨百翰大学（Brigham Young University）获得工商管理硕士学位，在那里他以优等成绩毕业，并被评为杰出的工商管理硕士毕业生。
- James Nelson has been a member of Co Diagnostics, Inc.'s board of directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms' portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company wide marketing, as well as the company's international expansion initiative. He was also general manager for Banana Republic's catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi billion dollar food service company. Mr. Nelson began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate. Mr. Nelson's advice to the board of directors from his experiences as a chief executive officer, strategic advisor and knowledge of capital markets greatly benefits Co Diagnostics, Inc.'s Board of Directors.
高管简历
中英对照 | 中文 | 英文- Dwight Egan
DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation（无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商，面向27000名个人和专业投资者）的高级执行官（1995年至1999年）。他从1984年到1995年共同创立并担任Broadcasting International，Inc.的首席执行官和董事会主席，当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
Dwight Egan serves as Co Diagnostics, Inc.'s Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real time financial market data, news and sophisticated fixed income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.- DwightH.Egan自2013年4月以来一直担任高级职员和董事。Egan先生从1999年2月到现在一直从事私人投资业务。他曾担任Data Broadcasting Corporation（无线、实时金融市场数据、新闻和复杂的固定收益投资组合分析的领先供应商，面向27000名个人和专业投资者）的高级执行官（1995年至1999年）。他从1984年到1995年共同创立并担任Broadcasting International，Inc.的首席执行官和董事会主席，当时Data Broadcasting Corporation收购Broadcasting International并创建领先的金融新闻网站CBS MarketWatch并参与其首次公开募股。
- Dwight Egan serves as Co Diagnostics, Inc.'s Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real time financial market data, news and sophisticated fixed income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering.
- Brian Brown
Brian Brown于2021年2月成为Co Diagnostics，Inc.的首席财务官。自2020年7月至2021年2月，Brown先生在A Core Concrete Cutting，Inc.担任首席财务官，其职责包括监督公司的会计和财务部门、并购以及负责财务预测和预算编制。自2020年1月至2020年7月，Brown先生担任独立顾问。自2019年8月至2019年12月，Brown先生在型男仓库控股担任会计、财务和投资者关系副总裁，该公司是一家在纳斯达克 Global Select报告的上市公司，代码为SPWH，其职责包括监督公司的会计、财务和投资者关系部门，编制公司与SEC的年度、季度和当前报告，监督公司年度审计的各个方面，包括但不限于编制和审查审计支持时间表、编制财务报表和脚注，并为公司的独立审计师提供支持。从2009年10月至2019年8月，Brown先生担任型男仓库控股公司的财务总监，在那里他协助公司于2014年4月进行首次公开募股，以及进行非公开和二次公开募股、收购一批零售店以及准备公司向SEC提交的定期报告和当前报告并遵守《萨班斯奥克斯利法案》。从2005年5月到2009年10月，Brown先生担任富兰克林柯维产品的公司控制人，在那里他根据《萨班斯奥克斯利法案》第404条要求的控制标准开发和维护了公司对财务报告结构的内部控制。2001年7月至2005年5月，Brown先生在KPMG，LLP担任高级鉴证员，为多个行业的不同客户提供审计服务。Brown先生拥有犹他大学会计学文学学士学位和专业会计硕士学位。布朗先生是犹他州的持牌注册会计师。
Brian Brown became Co Diagnostics, Inc.'s Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A Core Concrete Cutting, Inc. where his duties included overseeing the company's accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From January 2020 to July 2020, Mr. Brown was an independent consultant. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman's Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company's accounting, treasury and investor relations departments, preparing the company's annual, quarterly and current reports with the SEC, overseeing all aspects of the company's annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company's independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman's Warehouse Holdings, Inc. where he assisted with the company's initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company's periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company's internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.- Brian Brown于2021年2月成为Co Diagnostics，Inc.的首席财务官。自2020年7月至2021年2月，Brown先生在A Core Concrete Cutting，Inc.担任首席财务官，其职责包括监督公司的会计和财务部门、并购以及负责财务预测和预算编制。自2020年1月至2020年7月，Brown先生担任独立顾问。自2019年8月至2019年12月，Brown先生在型男仓库控股担任会计、财务和投资者关系副总裁，该公司是一家在纳斯达克 Global Select报告的上市公司，代码为SPWH，其职责包括监督公司的会计、财务和投资者关系部门，编制公司与SEC的年度、季度和当前报告，监督公司年度审计的各个方面，包括但不限于编制和审查审计支持时间表、编制财务报表和脚注，并为公司的独立审计师提供支持。从2009年10月至2019年8月，Brown先生担任型男仓库控股公司的财务总监，在那里他协助公司于2014年4月进行首次公开募股，以及进行非公开和二次公开募股、收购一批零售店以及准备公司向SEC提交的定期报告和当前报告并遵守《萨班斯奥克斯利法案》。从2005年5月到2009年10月，Brown先生担任富兰克林柯维产品的公司控制人，在那里他根据《萨班斯奥克斯利法案》第404条要求的控制标准开发和维护了公司对财务报告结构的内部控制。2001年7月至2005年5月，Brown先生在KPMG，LLP担任高级鉴证员，为多个行业的不同客户提供审计服务。Brown先生拥有犹他大学会计学文学学士学位和专业会计硕士学位。布朗先生是犹他州的持牌注册会计师。
- Brian Brown became Co Diagnostics, Inc.'s Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A Core Concrete Cutting, Inc. where his duties included overseeing the company's accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From January 2020 to July 2020, Mr. Brown was an independent consultant. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman's Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company's accounting, treasury and investor relations departments, preparing the company's annual, quarterly and current reports with the SEC, overseeing all aspects of the company's annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company's independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman's Warehouse Holdings, Inc. where he assisted with the company's initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company's periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company's internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.
- Richard Abbott
Richard Abbott曾担任Advanced Conceptions，Inc.的总裁，该公司是一家私营医疗设备公司，专注于设计自动化仪器，以解决具有挑战性的跨学科问题。Advanced Conceptions是Co Diagnostics，Inc.的全资子公司。从2018年9月至2021年1月，Abbott先生是SaltRidge，LLC的合伙人，通过该公司，他向Advanced Conceptions提供管理服务和其他咨询服务。2017年8月至2018年8月，担任私人控股的Vilicus的首席技术官，Vilicus是一家以云为中心的室内农业物联网设备网络提供商。从2016年10月到2017年7月，Abbott先生担任Fenome的首席技术官，Fenome是一家私营公司，专注于通过生长和结果期间的环境控制来操纵室内农业作物的表型表达。杨百翰大学Abbott先生拥有沃顿商学院的工商管理硕士学位以及科学、机械工程硕士学位和机械工程学士学位。
Richard Abbott has served as President of Co Diagnostics since March 2024. Prior to being appointed as President, from January 2021 to March 2024, Mr. Abbott served as President of Advanced Conceptions, Inc., a privately held medical device company focused on the design of automated instruments that solve challenging cross disciplinary problems. Advanced Conceptions is a wholly owned subsidiary of Co Diagnostics, Inc. From September 2018 to January 2021, Mr. Abbott was a partner in SaltRidge, LLC through which he provided management services to Advanced Conceptions and other consulting services. From August 2017 to August 2018, he served as the Chief Technology Officer for privately held Vilicus, a cloud centered network provider of IoT devices for indoor agriculture. From October 2016 to July 2017, Mr. Abbott served as the Chief Technology Officer for Fenome, a private company focused on the manipulation of phenotypic expression of indoor agriculture crops via environmental control during growth and fruiting. Mr. Abbott holds a Master of Business Administration from The Wharton School and a Master of Science, Mechanical Engineering and a Bachelors Mechanical Engineering from Brigham Young University.- Richard Abbott曾担任Advanced Conceptions，Inc.的总裁，该公司是一家私营医疗设备公司，专注于设计自动化仪器，以解决具有挑战性的跨学科问题。Advanced Conceptions是Co Diagnostics，Inc.的全资子公司。从2018年9月至2021年1月，Abbott先生是SaltRidge，LLC的合伙人，通过该公司，他向Advanced Conceptions提供管理服务和其他咨询服务。2017年8月至2018年8月，担任私人控股的Vilicus的首席技术官，Vilicus是一家以云为中心的室内农业物联网设备网络提供商。从2016年10月到2017年7月，Abbott先生担任Fenome的首席技术官，Fenome是一家私营公司，专注于通过生长和结果期间的环境控制来操纵室内农业作物的表型表达。杨百翰大学Abbott先生拥有沃顿商学院的工商管理硕士学位以及科学、机械工程硕士学位和机械工程学士学位。
- Richard Abbott has served as President of Co Diagnostics since March 2024. Prior to being appointed as President, from January 2021 to March 2024, Mr. Abbott served as President of Advanced Conceptions, Inc., a privately held medical device company focused on the design of automated instruments that solve challenging cross disciplinary problems. Advanced Conceptions is a wholly owned subsidiary of Co Diagnostics, Inc. From September 2018 to January 2021, Mr. Abbott was a partner in SaltRidge, LLC through which he provided management services to Advanced Conceptions and other consulting services. From August 2017 to August 2018, he served as the Chief Technology Officer for privately held Vilicus, a cloud centered network provider of IoT devices for indoor agriculture. From October 2016 to July 2017, Mr. Abbott served as the Chief Technology Officer for Fenome, a private company focused on the manipulation of phenotypic expression of indoor agriculture crops via environmental control during growth and fruiting. Mr. Abbott holds a Master of Business Administration from The Wharton School and a Master of Science, Mechanical Engineering and a Bachelors Mechanical Engineering from Brigham Young University.